Profile data is unavailable for this security.
About the company
Serina Therapeutics, Inc., formerly AgeX Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Its POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. Its POZ Platform partners are at the forefront in advancing LNP delivery technology to develop RNA therapeutics. The Company is focused on the advancement of its lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinson’s Disease through pre-clinical studies. The Company intends to advance SER 252 into Phase I clinical trials.
- Revenue in USD (TTM)137.00k
- Net income in USD-20.96m
- Incorporated2017
- Employees4.00
- LocationSerina Therapeutics Inc1101 MARINA VILLAGE PARKWAY, SUITE 201ALAMEDA 94501United StatesUSA
- Phone+1 (510) 671-8370
- Websitehttps://www.agexinc.com/
More ▼
Mergers & acquisitions
| Acquired company | SER:ASQ since announced | Transaction value |
|---|---|---|
| Serina Therapeutics Inc | -61.71% | 90.00m |
Data delayed at least 15 minutes, as of May 21 2024 15:55 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Passage Bio Inc | 0.00 | -84.44m | 80.71m | 58.00 | -- | 0.7695 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -47.73 | -48.56 | -52.17 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Elutia Inc | 25.05m | -49.46m | 81.82m | 54.00 | -- | -- | -- | 3.27 | -2.35 | -2.34 | 1.24 | -2.07 | 0.5219 | 2.06 | 4.27 | 463,833.30 | -103.05 | -42.93 | -599.50 | -79.34 | 42.01 | 43.32 | -197.48 | -64.16 | 0.5499 | -1.36 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| Assembly Biosciences Inc | 12.95m | -51.36m | 82.48m | 65.00 | -- | 2.52 | -- | 6.37 | -11.22 | -11.22 | 2.76 | 5.95 | 0.1276 | -- | 34.07 | 199,200.00 | -50.60 | -39.69 | -66.58 | -44.03 | -- | -- | -396.63 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Spero Therapeutics Inc | 110.98m | 23.40m | 84.07m | 46.00 | 3.70 | 0.8731 | 3.55 | 0.7576 | 0.4213 | 0.4213 | 2.08 | 1.79 | 0.792 | -- | 3.96 | 2,412,565.00 | 16.70 | -35.52 | 21.73 | -41.75 | -- | -- | 21.09 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -28.77m | 84.12m | 25.00 | -- | 2.91 | -- | -- | -0.9155 | -0.9155 | 0.00 | 0.7218 | 0.00 | -- | -- | 0.00 | -68.08 | -- | -85.18 | -- | -- | -- | -- | -- | -- | -251.59 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| Serina Therapeutics Inc | 137.00k | -20.96m | 84.14m | 4.00 | -- | -- | -- | 614.15 | -14.07 | -14.07 | 0.0909 | -0.5121 | 0.0117 | -- | 3.86 | 34,250.00 | -179.27 | -194.46 | -- | -- | 67.88 | 85.80 | -15,301.46 | -2,347.36 | -- | -0.9274 | 1.70 | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
| Aclaris Therapeutics Inc | 31.12m | -77.26m | 84.81m | 91.00 | -- | 0.597 | -- | 2.73 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| vTv Therapeutics Inc | 1.00m | -20.62m | 84.92m | 16.00 | -- | 4.08 | -- | 84.92 | -8.76 | -8.76 | 0.383 | 6.91 | 0.0241 | -- | 2.04 | 62,500.00 | -63.15 | -111.84 | -128.59 | -- | -- | -- | -2,621.10 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| Sellas Life Sciences Group Inc | 0.00 | -35.81m | 85.48m | 16.00 | -- | 8.60 | -- | -- | -1.12 | -1.12 | 0.00 | 0.1721 | 0.00 | -- | -- | 0.00 | -133.77 | -111.48 | -303.59 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Atara Biotherapeutics Inc | 34.70m | -233.11m | 85.50m | 173.00 | -- | -- | -- | 2.46 | -2.12 | -2.12 | 0.3016 | -0.817 | 0.1485 | 0.9947 | 1.92 | 154,240.00 | -99.76 | -70.20 | -213.09 | -86.94 | 69.30 | -- | -671.70 | -1,559.33 | 0.50 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Chimerix Inc | 41.00k | -82.59m | 88.35m | 72.00 | -- | 0.5075 | -- | 2,154.83 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Allovir Inc | 0.00 | -179.53m | 88.43m | 112.00 | -- | 0.7334 | -- | -- | -1.65 | -1.65 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -92.50 | -52.85 | -100.98 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
Data as of May 21 2024. Currency figures normalised to Serina Therapeutics Inc's reporting currency: US Dollar USD
4.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Broadwood Capital, Inc.as of 31 Mar 2024 | 85.22k | 3.41% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 19.58k | 0.78% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.53k | 0.14% |
| British & American Investment Trust Plc (Invt Mgmt)as of 30 Jun 2023 | 2.92k | 0.12% |
| Strategic Wealth Designers LLCas of 31 Dec 2023 | 2.77k | 0.11% |
| Virtu Americas LLCas of 31 Dec 2023 | 816.00 | 0.03% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2024 | 656.00 | 0.03% |
| Tower Research Capital LLCas of 31 Mar 2024 | 448.00 | 0.02% |
| Vanguard Global Advisers LLCas of 31 Mar 2024 | 368.00 | 0.02% |
| Wells Fargo Securities LLCas of 31 Mar 2024 | 49.00 | 0.00% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
